



Proteomics International

LABORATORIES LTD

ASX Release
23 February 2026

ASX code: PIQ

Resignation of Dr Richard Lipscombe

Proteomics International Laboratories Ltd (Proteomics International or the Company; ASX: PIQ) refers to its ASX Announcement of 14 January 2026. As noted in the announcement, Dr Richard Lipscombe, today formally retires from his position as a Director of the Company following 25 years of distinguished leadership as founder and Managing Director. Dr Lipscombe has been instrumental in establishing Proteomics International as a global leader in precision diagnostics.

An Appendix 3Z, final director's interest notice follows this announcement.

Authorised by the Chair of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr James Williams
Chairman
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Matthew Wright
Media and Public Relations
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Dirk van Dissel
Investor Relations & Corporate Advisory
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Proteomics International Laboratories Ltd
ABN:	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Richard Lipscombe
Date of last notice	13 June 2025
Date that director ceased to be director	23 February 2026

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
7,564,859 Shares 162,162 PIQO Listed Options

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Z
Final Director's Interest Notice

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest</p> <p>Dr Richard John Lipscombe <The LUK A/C> Dr Lipscombe is the trustee and a beneficiary of the trust</p>	<p>7,881,996 Shares 202,703 PIQO Listed Options</p>
<p>Bjouxz Pty Ltd <The Loz Superannuation Fund> Dr Lipscombe is beneficiary of the superannuation fund and sole director and shareholder of the trustee.</p>	<p>1,700,000 Shares 1,000,000 Tranche A Executive Options 800,000 Tranche B Executive Options 800,000 Tranche C Executive Options</p>

Part 3 - Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.

For personal use only